Aveo pharmaceuticals, inc. (AVEO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Revenues

28,795

5,409

7,579

2,515

-

-

-

-

-

-

-

Revenues

-

-

-

-

19,024

18,123

1,293

19,286

164,849

44,682

20,719

Operating expenses:
Research and development

17,958

20,652

25,179

23,703

12,875

38,254

68,468

91,358

101,735

86,345

51,792

General and administrative

11,211

10,781

9,138

8,205

10,217

18,589

28,712

36,932

29,167

14,763

10,120

Settlement costs (Note 13)

-

-667

2,073

-

4,000

-

-

-

-

-

-

Restructuring and lease exit

-

-

-

-

4,358

11,729

8,017

2,633

-

-

-

Operating expenses, total

29,169

30,766

36,390

31,908

31,450

68,572

105,197

130,923

130,902

101,108

61,912

Loss from operations

-374

-25,357

-28,811

-29,393

-12,426

-50,449

-103,904

-111,637

33,947

-56,426

-41,193

Other income, net:
Interest expense, net

1,815

2,191

2,373

1,949

2,286

2,356

3,127

3,501

3,836

3,389

2,811

Change in fair value of PIPE Warrant liability

-11,577

-19,919

33,740

-4,751

-

-

-

-

-

-

-

Other income

-

2,300

-

-195

-289

66

-123

247

10

900

-333

Interest income

-

-

-

-

-

-

125

497

527

126

144

Other income, net

9,762

20,028

-36,113

2,607

-2,575

-2,290

-3,125

-2,757

-3,299

-2,363

-3,000

Net income (loss) before provision for income taxes

9,388

-5,329

-64,924

-26,786

-15,001

-52,739

-

-

-

-

-44,193

Provision for income taxes

0

0

101

101

-

-

-

-

-

-

-100

Net income (loss)

9,388

-5,329

-65,025

-26,887

-15,001

-52,739

-107,029

-114,394

30,648

-58,789

-44,093

Net loss per share - basic and diluted

-

-

-

-

-0.27

-1.01

-2.10

-2.64

-

-

-

Weighted average number of common shares outstanding basic and diluted

-

-

-

-

55,701

52,289

50,928

43,374

-

-

-

Basic net income (loss) per share
Net income (loss) per share

0.61

-0.44

-6.14

-0.39

-

-

-

-

0.77

-2.30

-27.43

Weighted average number of common shares outstanding

15,331

12,059

10,593

69,268

-

-

-

-

39,715

25,582

1,607

Diluted net income (loss) per share
Net income (loss) per share

0.61

-1.93

-6.14

-0.39

-

-

-

-

0.74

-2.30

-27.43

Weighted average number of common shares and dilutive common share equivalents outstanding

15,376

13,073

10,593

69,268

-

-

-

-

41,473

25,582

1,607

Collaboration and Licensing Revenue
Revenues

27,934

4,947

7,560

2,515

-

-

-

-

-

-

-

Partnership Royalties
Revenues

861

462

19

-

-

-

-

-

-

-

-